Oruka Therapeutics, Inc.
ORKA
$68.57
$1.642.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -31.82M | -29.58M | -30.28M | -24.57M | -21.00M |
| Total Depreciation and Amortization | 43.00K | 28.00K | 20.00K | 19.00K | 16.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.67M | 3.59M | 9.26M | 3.70M | 3.15M |
| Change in Net Operating Assets | 1.53M | 3.37M | -602.00K | -2.29M | -3.03M |
| Cash from Operations | -23.58M | -22.59M | -21.60M | -23.15M | -20.87M |
| Capital Expenditure | -73.00K | -63.00K | -99.00K | -34.00K | -13.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.36M | -21.96M | -122.35M | 4.89M | 42.88M |
| Cash from Investing | -14.44M | -22.02M | -122.45M | 4.86M | 42.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 40.60M | 298.00K | 169.91M | 109.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40.60M | 298.00K | 169.91M | 109.00K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.59M | -44.32M | 25.86M | -18.18M | 22.00M |